Oxaliplatin Kelix Bio

Oxaliplatin, the active ingredient in Oxaliplatin Kelix Bio, is a platinum‑based chemotherapy presented as a strength/form for intravenous use. It treats colorectal cancer and is used in adult patients undergoing combination chemotherapy regimens.

GNH USA supplies Oxaliplatin Kelix Bio as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin Kelix Bio is a platinum‑based chemotherapeutic agent used in the treatment of cancers that respond to DNA‑cross‑linking therapy. - Colorectal cancer: improves survival when combined with fluoropyrimidine‑based regimens. - Gastric cancer: used in combination protocols for advanced disease. - Pancreatic cancer: part of multi‑drug regimens for metastatic cases.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, depending on individual tolerance and treatment context.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Fatigue: general tiredness during treatment cycles. - Diarrhea: loose stools that may require supportive care. - Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical attention. - Hematologic toxicity: neutropenia or thrombocytopenia increasing infection or bleeding risk. - Acute pulmonary toxicity: rare lung inflammation presenting with cough or dyspnea. - Cardiac arrhythmias: uncommon but potentially life‑threatening rhythm disturbances. - Renal impairment: worsening kidney function, especially with pre‑existing disease.

When using Oxaliplatin Kelix Bio, clinicians should assess patient suitability and monitor for known risks. - Renal function: evaluate creatinine clearance before each cycle. - Hepatic function: check liver enzymes and bilirubin regularly. - Neuropathy monitoring: assess sensory changes and adjust dosing if needed. - Hematologic surveillance: perform complete blood counts to detect neutropenia or thrombocytopenia. - Allergic reactions: be prepared to manage infusion‑related hypersensitivity. - Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, influencing efficacy or safety.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney damage. - High‑dose vitamin C infusions: may reduce platinum‑drug activity.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): heightened bleeding risk due to thrombocytopenia. - Antiemetics (ondansetron, dexamethasone): may require dose adjustments for optimal control. - CYP450 inducers (rifampicin): potential alteration of drug clearance. - Immunosuppressants (cyclophosphamide): additive bone‑marrow suppression. - NSAIDs (ibuprofen, naproxen): may exacerbate renal toxicity.